RightFit
RecruitingPhase 4

PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy

Postpartum Evaluation of Antihypertensive Cessation and Efficacy (PEACE): A Randomized Controlled Trial Comparing Oral Labetalol and Oral Extended-Release Nifedipine for Managing Postpartum Hypertension

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 64 Years
Sex
Female only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares labetalol and long-acting nifedipine for high blood pressure after childbirth. It will test which medicine controls blood pressure better and reduces the need for medicine beyond six weeks after birth. The 110 participants will be assigned by chance to one medicine, and their blood pressure will be checked remotely.

This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for continued medication beyond six weeks postpartum. The study will enroll 110 postpartum participants, randomly assigning them to one of the two medications, with remote blood pressure monitoring to evaluate treatment effectiveness and inform postpartum hypertension management.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be at least 18 years old.
  • Give birth at the study hospital at 28 weeks of pregnancy or later.
  • After birth, have a top blood pressure number above 150 or a bottom number above 100; or have at least two readings within 24 hours with a top number above 140 or a bottom number above 90.
  • Need to start blood pressure medicine by mouth during the hospital stay after birth or within 7 days of leaving the hospital.
  • Have a pregnancy care team that agrees to start either study medicine.

Who can't join

  • Took blood pressure medicine by mouth before giving birth.
  • Have a known allergy or another medical reason not to take nifedipine or labetalol.
  • Have a history of ongoing moderate to severe asthma, chronic obstructive pulmonary disease (a long-term lung disease), or heart failure.
  • Have a history of heart block more severe than first-degree heart block (a problem with the heart's electrical signals).
  • Cannot give written informed consent in English, meaning written agreement to join after learning about the study.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion criteria: Age ≥18 years Delivery at study institution at ≥28 weeks gestation Postpartum SBP \> 150 and/or DBP \> 100 OR 2 or more SBP \> 140 and/or DBP \> 90 within a 24-hour period Require initiation of an oral antihypertensive medication during postpartum hospital stay or within 7 days of discharge Treating obstetric team amenable to starting either study medication Exclusion criteria: Treated with oral antihypertensive medications prior to delivery Known allergies or contraindications to nifedipine or labetalol History of moderate persistent to severe asthma, chronic obstructive pulmonary disease, heart failure, or greater than first-degree atrioventricular heart block Unable to provide written informed consent in English

Study sites (1)

CA